Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis
- 1 January 2009
- journal article
- review article
- Published by Informa UK Limited in Annals of Medicine
- Vol. 41 (5), 332-343
- https://doi.org/10.1080/07853890902769675
Abstract
Risk stratification for cardiovascular diseases (CVD) remains suboptimal even after the introduction of global risk assessment by various scores. This has prompted the search for additional biomarkers which might help to improve risk stratification. Basically, there are blood biomarkers representing various pathophysiological pathways of atherosclerosis, and markers of subclinical disease. Since inflammatory processes accompany all stages of atherosclerosis, measurement of plasma/serum concentrations of circulating inflammatory biomarkers have received great attention. Such biomarkers can be measured systemically by sensitive assays, and elevated concentrations in the circulation have been shown to be associated with future CVD events. Thus, they might add to the predictive value of the atherogenic lipoprotein phenotype to further improve CVD risk assessment. In addition, several non-invasive imaging techniques are available for which also a predictive value for CVD could be established. However, for most of these biomarkers the clinical utility has not yet been firmly established. This review attempts to give an update on the potential use of biomarkers for risk stratification in initially healthy subjects and patients with manifest, chronic atherosclerosis, particularly focusing on the integrated value of the combination of these markers.Keywords
This publication has 65 references indexed in Scilit:
- Are We Getting Nearer to Screening for Atherosclerosis?Cell Metabolism, 2008
- The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseasesEuropean Journal of Epidemiology, 2007
- Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular OutcomesArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Lipoprotein-Associated Phospholipase A2 Predicts 5-Year Cardiac Mortality Independently of Established Risk Factors and Adds Prognostic Information in Patients with Low and Medium High-Sensitivity C-Reactive Protein (The Ludwigshafen Risk and Cardiovascular Health Study)Clinical Chemistry, 2007
- Relative Value of Inflammatory, Hemostatic, and Rheological Factors for Incident Myocardial Infarction and StrokeCirculation, 2007
- Subclinical Cardiovascular Disease Markers Applicable to Studies of Oral Health: Multiethnic Study of AtherosclerosisAnnals of the New York Academy of Sciences, 2007
- A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in MusclePLOS ONE, 2006
- Serum Concentrations of Adiponectin and Risk of Type 2 Diabetes Mellitus and Coronary Heart Disease in Apparently Healthy Middle-Aged Men: Results From the 18-Year Follow-Up of a Large Cohort From Southern GermanyJournal of the American College of Cardiology, 2006
- Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular EventsCirculation, 2006
- C-Reactive Protein, Fibrin D-Dimer, and Risk of Ischemic Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2004